

Certificate of Analysis

CaM Kinase I γ , active (Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-967, 14-967-K, 14-967M

Parent Lot # D15MP006N

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal GST-tagged, recombinant, human CaM Kinase I γ full length, expressed by baculovirus in Sf21 insect cells. Purified using glutathione agarose.

Purity 74% by SDS-PAGE and Coomassie blue staining. MW = 80kDa.

Specific Activity (Parent lot# D15MP006N): 2386U/mg, where one unit of CaM Kinase I γ , active activity is defined as 1nmol phosphate incorporated into 250 μ M KKLNRTLSFAEPG per minute at 30°C with a final ATP concentration of 100 μ M.

Formulation: 0.70mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 0–17ng of this lot of enzyme phosphorylated 250 μ M KKLNRTLSFAEPG in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as CaM Kinase I γ with the translated sequence listed on page three.



SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3 μ g of CaM Kinase I γ , active.

Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

- 5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
- KKLNRTLSEFAEPG:** Use at a final assay concentration of 250µM. Prepare a 2.5mM stock and add 2.5µl of stock per assay point.
- Calcium Chloride:** Use at a final assay concentration of 0.5mM. Prepare a 50mM stock and use 0.25µl per assay point.
- Calmodulin:** Use at a final assay concentration of 0.016mg/ml. Prepare a 0.3mg/ml stock and use 1.325µl per assay point.
- CaM Kinase I γ , active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 0–17ng per assay point.
- [γ -³³P]ATP:** 2.5 x MgAc/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required).

Assay Procedure (96 well plate format):

- Add 5µl of 5 x reaction buffer per assay to wells.
- Add 3.425µl of dH₂O.
- Add 0.25µl of 50mM calcium chloride.
- Add 1.325µl of 0.3mg/ml calmodulin.
- Add 2.5µl of **KKLNRTLSEFAEPG**
- Add **2.5µl (0–17ng) CaM Kinase I γ , active.**
- Add 10µl of diluted [γ -³³P]ATP mixture.
- Incubate for 10 minutes at 30°C.
- Stop the reaction by adding 5µl of 3% phosphoric acid.
- Transfer a 10µl aliquot onto the appropriate area of a P30 Filtermat.
- Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
- Wash the filtermat once for 2 minutes with methanol.
- Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
- Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

CaM Kinase I γ , active Sequence Information

<u>Protein</u>	Human CaM Kinase I γ
<u>Tags</u>	N-terminal GST
<u>Native sequence</u>	M231 of the recombinant protein is equivalent to M1 of human CaM Kinase I γ
<u>Accession number</u>	GenBank NM_020439.2

Recombinant CaM Kinase I γ amino acid sequence:

```

1  MSPILGYWKI  KGLVQPTRL  LEYLEEKYEE  HLYERDEGDK  WRNKKFELGL  EFPNLPYYID
61  GDVKLTQSMA  IIRYIADKHN  MLGGCPKERA  EISMLEGAVL  DIRYGVSRIA  YSKDFETLKV
121  DFLSKLP EML  KMFEDRLCHK  TYLNGDHVTH  PDFMLYDALD  VVLYMDPMCL  DAFPKLVCFK
181  KRIEAIPQID  KYLKSSKYIA  WPLQGWQATF  GGDHPPKSD  LEVLFQGP EF  MGRKEEDDCS
241  SWKKQTTNIR  KTFIFMEVLG  SGAFSEVFLV  KQRLTGKLF  A  LKCIKSPAF  RDSSLENEIA
301  VLKKIKHENI  VTLEDIYEST  THYYLVMQLV  SGGELFDRI  L  ERGVYTEKDA  SLVIQQVLSA
361  VKYLHENGIV  HRDLKPENLL  YLTPEENSKI  MITDFGLSKM  EQNGIMSTAC  GTPGYVAPEV
421  LAQKPYSKAV  DCWSIGVITY  ILLCGYPPFY  EETESKLF EK  IKEGYEFES  PFWDDISESA
481  KDFICHLLEK  DPNERYTCEK  ALSHPWIDGN  TALHRDIYPS  VSLQIQKNFA  KSKWRQAFNA
541  AAVVHMRK L  HMNLHSPGVR  PEVENRPPET  QAS ETSRPS S  PEITITEAPV  LDHSVALPAL
601  TQLPCQHGR R  PTAPGGRSLN  CLVNGSLHIS  SSLVPMHQGS  LAAGPCGCCS  SCLNIGSKGK
661  SSYCSEPTLL  KKANKKQNFK  SEVMVPVKAS  GSSHCRAGQT  GVCLIM
  
```

Recombinant CaM Kinase I γ nucleotide sequence:

```

1  atgtccccta  tactaggtta  ttggaaaatt  aagggccttg  tgcaaccac  cgcacttctt
61  ttggaatatt  ttgaagaaaa  atatgaagag  catttgtagt  agcgcgatga  aggtgataaa
121  tggcgaaaca  aaaagtttga  attgggtttg  gagtttccca  atcttcctta  ttatattgat
181  ggtgatgtta  aattaacaca  gtctatggcc  atcatacgtt  atatagctga  caagcacaac
241  atgttgggtg  gttgtccaaa  agagcgtgca  gagatttcaa  tgcttgaagg  agcggttttg
301  gatattagat  acggtgtttc  gagaattgca  tatagtaaag  actttgaaac  tctcaaagtt
361  gattttctta  gcaagctacc  tgaaatgctg  aaaatgttcg  aagatcgttt  atgtcataaa
421  acatatttaa  atggtgatca  tgtaaccat  cctgacttca  tgttgtagta  cgctcttgat
481  gttgttttat  acatggacc  aatgtgcctg  gatgcgttcc  caaaattagt  ttgttttaa
541  aaacgtattg  aagctatccc  acaaattgat  aagtagctga  aatccagcaa  gtatatagca
601  tggcctttgc  agggctggca  agccacgttt  ggtggtggcg  accatcctcc  aaaatcggat
661  ctggaagtcc  tgttccaggg  gcccgaaatt  atgggtcgaa  aggaagaaga  tgactgcagt
721  tcctggaaga  aacagaccac  caacatccgg  aaaaccttca  tttttatgga  agtgctggga
781  tcaggagctt  tctcagaagt  tttcctgggt  aagcaaagac  tgactgggaa  gctctttgct
841  ctgaagtgca  tcaagaagtc  acctgccttc  cgggacagca  gcctggagaa  tgagattgct
901  gtgttgaaaa  agatcaagca  tgaaaacatt  gtgaccctgg  aggacatcta  tgagagcacc
961  acccactact  acctggtcat  gcagcttggt  tctggtgggg  agctctttga  ccggatcctg
1021  gagcgggggt  tctacacaga  gaaggatgcc  agtctggtga  tccagcaggt  cttgtcggca
1081  gtgaaatacc  tacatgagaa  tggcatcgct  cacagagact  taaagcccg  aaacctgctt
1141  taccttacc  ctgaagagaa  ctctaagatc  atgatcactg  actttggtct  gtccaagatg
1201  gaacagaatg  gcatcatgtc  cactgcctgt  gggaccccag  gctacgtggc  tccagaagtg
1261  ctggcccaga  aaccctacag  caaggctgtg  gattgctggt  ccatcggcgt  catcacctac
1321  atattgctct  gtggataacc  cccgttctat  gaagaaacgg  agtctaagct  tttcgagaag
1381  atcaaggagg  gctactatga  gtttgagtct  ccattctggg  atgacatttc  tgagtcagcc
1441  aaggacttta  tttgccactt  gcttgagaag  gatccgaacg  agcggtagac  ctgtgagaag
1501  gccttgagtc  atccctggat  tgacggaaac  acagccctcc  accgggacat  ctaccatca
  
```

Certificate of Analysis

```
1561 gtcagcctcc agatccagaa gaactttgct aagagcaagt ggaggcaagc cttcaacgca
1621 gcagctgtgg tgcaccacat gaggaagcta cacatgaacc tgcacagccc gggcgtccgc
1681 ccagaggtgg agaacaggcc gcctgaaact caagcctcag aaacctctag acccagctcc
1741 cctgagatca ccatcaccga ggcacctgtc ctggaccaca gtgtagcact ccctgcctg
1801 acccaattac cctgccagca tggccgcccgg cccactgccc ctggtggcag gtcctcaac
1861 tgctgtgtca atggctccct ccacatcagc agcagcctgg tgcccatgca tcaggggtcc
1921 ctggccgccc ggccctgtgg ctgctgctcc agctgcctga acattgggag caaaggaaag
1981 tcctcctact gctctgagcc cacactcctc aaaaaggcca acaaaaaaca gaacttcaag
2041 tcggaggtca tgggtaccagt taaagccagt ggcagctccc actgcccgggc agggcagact
2101 ggagtctgtc tcattatgtg a
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.